
|Videos|June 29, 2017
Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC
Author(s)Jordi Bruix, MD
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.
Advertisement
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma (HCC).
The updated overall survival results for the phase III RESORCE trial of regorafenib (Stivarga) were presented at the 2017 World Congress on Gastrointestinal Cancer.
This longer follow-up has confirmed that regorafenib is an effective treatment for patients with HCC who have progressed on sorafenib (Nexavar).
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































